

BARROW HANLEY GLOBAL EQUITY TRUST

March 2025



FUND FACTS

Investment return objective: Aims to provide the trust with higher returns compared to the benchmark, while maintaining lower risk.

FUND BENEFITS


True traditional value portfolio concentrated in 50-70 stocks which focuses on undervalued companies with improving operating fundamentals identified by Barrow Hanley's screening process.

FUND RISKS

All investments carry risk and different strategies may carry different levels of risk. The relevant product disclosure statement or offer document for a fund should be considered before deciding whether to acquire or hold units in that fund. Your financial adviser can assist you in determining whether a fund is suited to your financial needs.

| | |
|--------------------------------------|------------------------------------|
| Benchmark: | MSCI World Index (Measured in AUD) |
| Inception date: | 6/05/2016 |
| Delegated Investment Manager: | Barrow Hanley Mewhinney & Strauss |
| APIR: | ETLo434AU |
| Management Fee: | 0.99% p.a |
| Size of fund | \$ 276.42 million as at 31/12/2024 |
| Suggested minimum investment period: | Five years or longer |

PORTFOLIO SECTORS



NET PERFORMANCE - Periods ending March 31, 2025


| | Fund | Benchmark | Excess |
|-----------------|------|-----------|--------|
| 1 month | 0.1 | -4.6 | +4.65 |
| 3 months | 5.0 | -2.3 | +7.28 |
| FYTD | 19.7 | 12.1 | +7.59 |
| 1 year | 15.3 | 12.6 | +2.74 |
| 2 years | 16.7 | 20.5 | -3.80 |
| 3 years | 14.7 | 15.0 | -0.36 |
| 4 years | 12.5 | 14.3 | -1.83 |
| 5 years | 16.0 | 16.3 | -0.21 |
| Since Inception | 12.0 | 13.8 | -1.78 |

Past performance is not indicative of future performance. Returns may differ due to different tax treatments.

TOP 5 STOCK HOLDINGS

| | % of Portfolio |
|---------------------|----------------|
| SANOFI SA | 3.4% |
| MERCK & CO INC | 3.0% |
| BANK OF NOVA SCOTIA | 2.8% |
| STANDARD CHARTERED | 2.4% |
| ELEVANCE HEALTH INC | 2.3% |

PORTFOLIO REGIONS



Looking back, the first quarter of 2025 was the third worst start to the year for the S&P 500 since the Global Financial Crisis 15 years ago. What began optimistically ended with uncertainty—as market euphoria over deregulation and lower taxes promised by the incoming Trump administration was swiftly swept aside by widespread concerns over austerity, inflation, and tariffs. For the broad U.S. market, this marked a sharp reversal for the Magnificent 7, which dragged down the S&P 500 index given the high concentration in those names and leading to a new nickname entering investors’ lexicon, the “Lag 7”. The first quarter saw six consecutive weekly declines for the group of seven while six out of the seven underperformed the broader S&P 500 in the quarter. During the quarter, the Barrow Hanley Global Value Equity strategy posted very strong results, outpacing the MSCI World Index by more than 700 bps and the MSCI World Value Index by more than 100 bps. Relative to the MSCI World Index, the allocation to value stocks with an underweight to the Information Technology sector and an overweight to the Utilities and Energy sectors contributed to relative returns.

Defence holdings Rheinmetall AG and BAE Systems plc outperformed very strongly in the first quarter as expectations for growth in European defence spending continue to go higher. President Trump and his new administration continue to exert more pressure than expected on Europe to spend more on its own defence. The discussion is moving from getting European NATO spending to 2% of GDP to at least 3% with Trump talking about a need for 5%. Following the CDU win in the German elections, the Bundestag also approved an exemption for defence spending from the debt break. That paves the way for sustainably higher spending as Germany rebuilds its defence capabilities.

Newmont Corporation positively contributed to relative performance during the quarter due to several key factors. The company reported better-than-expected Q4 earnings, driven by a significant increase in gold production and prices, which led to a surge in its stock price. Gold prices began the quarter at \$2,639 per ounce and ended at \$3,157 per ounce, reflecting a strong market environment. Additionally, Newmont completed the sale of several operations, generating \$1.7 billion in after-tax cash proceeds, as part of its strategic portfolio optimisation as the company continues to execute on its plan to fund buybacks and reduce debt levels through the sale of higher cost mines.

Microchip Technology Incorporated detracted from relative performance during the quarter due to elevated inventory throughout the channel and underutilization charges weighing on orders and gross margins. The company, which designs and manufactures microcontrollers and analog semiconductors, reported a 42% yearover-year and 12% quarter-over-quarter decline in revenue. Inventory levels at customers, channel partners, and downstream partners have not yet bottomed out, contributing to the company's challenges. Despite proactive measures to manage fixed costs and inventory, the March quarter outlook missed expectations. As the semiconductor cycle turns, Microchip is well positioned to participate in the rebound and the stock has a dividend yield of 3.8%.

Avantor, Inc. detracted from relative performance during the quarter as excitement around a bioprocessing recovery was met with cautious guidance by the company and peers. In addition, concerns around NIH funding cuts weighed on Avantor despite <5% exposure to the U.S. academic market. Avantor is a vertically integrated supplier to the global life sciences and applied materials industries. While there remains skepticism around the cadence of a short-term recovery in industry volumes, the worst of de-stocking is likely behind us. Sales and earnings are poised to re-accelerate, and the company is well positioned to benefit from longer term secular growth in bioprocessing volumes.

Looking ahead, markets are grappling with an unusually high degree of uncertainty. If the past five years have taught investors anything, it’s how to navigate through volatility and rapid change. Tariffs targeting major U.S. trading partners appear more severe than expected, reinforcing a reset at lower baselines. Rising tensions between the U.S. and China have stirred fears of a broader trade war, shaking investor confidence and increasing the risk of a global recession. Growth forecasts in the U.S. have softened, and inflation remains uncertain—caught between elevated input costs and declining consumer and corporate demand. Markets hoping for a swift Fed response may need to be patient. Chairman Powell’s call for restraint as developments unfold has done little to ease nerves. Meanwhile, the unwind of the long-standing momentum trade is beginning. Indices like the S&P 500 remain concentrated in growth stocks and the “Mag 7,” a dynamic that will take time to normalize. As this shift plays out, value-oriented areas—especially cyclical names—look increasingly well-positioned for the road ahead.

Equity Trustees Limited (Equity Trustees) ABN 46 004 031 298 | AFSL 240975 is the Responsible Entity for the Barrow Hanley Global Equity Trust (the Fund). Equity Trustees is a subsidiary of EQT Holdings Limited ABN 22 607 797 615, a publicly listed company on the Australian Securities Exchange (ASX: EQT). The Investment Manager for the Fund is Perpetual Investment Management Limited (Perpetual) ABN 18 000 866 535 | AFSL 234426. Perpetual has delegated the investment management of the Fund to Barrow, Hanley, Mewhinney & Strauss, LLC (BH). This information has been prepared by Perpetual to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Perpetual, BH, Equity Trustees nor any of their related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accept any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. The PDS can be obtained by calling 1800 022 033 or visiting our website www.perpetual.com.au. Barrow Hanley Global Equity Trust's Target Market Determination available here. A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.

MORE INFORMATION

Adviser Services 1800 062 725
Investor Services 1800 022 033
Email investments@perpetual.com.au
www.perpetual.com.au

